About the Company
We do not have any company description for INTENSITY THERAPEUTICS, INC. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on INTENSITY THERAPEUTICS, INC.
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...
Intensity Therapeutics, Inc. Announces the Appointment of ... - Nasdaq
--Intensity Therapeutics, Inc., a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to ...
Intensity Therapeutics Amends Bylaws for Quorum Change
The latest update is out from Intensity Therapeutics, Inc. ( ($INTS) ). On August 12, 2025, Intensity Therapeutics, Inc. amended its bylaws to ...
Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Over $11 million raised since the beginning of 2Q 2025 Cash runway extended into the second half of 2026 In the INVINCIBLE-4 Study, patients receiving INT230-6 ...
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin ...
May 15, 2024 8:01 AM ETIntensity Therapeutics, Inc. (INTS) INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was ...
Intensity Therapeutics, Inc. to Collaborate with Author, Model ...
SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% ...
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics, Inc. Announces the Closing and Full ... - Nasdaq
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds ...
Intensity Therapeutics, Inc. Announces Proposed Public Offering of ...
SHELTON, Conn., June 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and ...
Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company ...
Similar Companies
Loading the latest forecasts...